Tactile Systems Technology, Inc. announced on September 25, 2024, the publication of a new clinical study in the Journal of Vascular Surgery, Venous and Lymphatic Disorders. This study assessed outcomes associated with the use of the company’s Flexitouch advanced pneumatic compression device (APCD) in Veterans with lower extremity lymphedema.
The 52-week study represents the largest peer-reviewed, prospective, clinical trial investigating pneumatic compression devices and lymphedema ever published in the United States. It included 179 Veterans across four VA medical centers, with chronic venous insufficiency being the most common etiology of lymphedema in approximately 63% of participants.
The study demonstrated significant improvements in health-related and general quality of life measures, with Lymphedema Quality of Life (QoL) increasing from 6.2 to 6.9. Additionally, secondary endpoints showed statistically significant reductions in limb girth, cellulitis events, and skin hyperpigmentation from baseline to 52 weeks, validating the importance of APCD therapy outcomes and patient adherence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.